ArticleCureus2026
Stereotactic Body Radiotherapy as a Salvage Treatment for Regional Lymph Node Recurrence of Cervical Cancer: Two Case Reports With Complete Metabolic Response and Literature Review.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Locoregional and regional nodal recurrence remains a major therapeutic challenge in cervical cancer, particularly in patients previously treated with pelvic radiotherapy, where salvage options are limited by cumulative toxicity to surrounding organs at risk. In selected patients with limited-volume recurrent disease, stereotactic body radiotherapy (SBRT) has emerged as a highly conformal salvage approach capable of delivering ablative radiation doses while minimizing exposure to adjacent normal tissues. We report two cases of limited-volume regional nodal recurrence from cervical squamous cell carcinoma successfully managed with SBRT. The first patient, a 32-year-old woman initially diagnosed with International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IIIC1 disease, developed multifocal pelvic and para-aortic lymph node recurrence 12 months after completion of definitive treatment. The second patient, a 48-year-old woman with FIGO 2018 stage IIB disease, presented with isolated para-aortic nodal recurrence after a 33-month disease-free interval. In both cases, recurrence was identified by fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.